USEUROPEAFRICAASIA 中文双语Français
Home / Business

GSK may shift some Relenza manufacturing to mainland

By Ma Zhenhuan | China Daily | Updated: 2009-11-19 08:07

SHANGHAI: British drugmaker GlaxoSmithKline (GSK) Plc is planning to move part of its flu drug Relenza manufacture to China to better support the local market.

"I hope that we will be able to shift some Relenza manufacture to China to make our products more accessible in the country," said Chief Executive Andrew Witty.

The drug, which received the State Food and Drug Administration (SFDA) approval in September for domestic sales, is used to fight the flu virus along with Roche's Tamiflu.

GSK may shift some Relenza manufacturing to mainland

Today's Top News

Editor's picks

Most Viewed

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US